
Opinion|Videos|June 29, 2024
Current Landscape of Biosimilar Use in US Healthcare Space
Dr Humphreys drives a conversation scoping the biosimilar landscape and available treatment options.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Provide an overview of the current landscape of FDA biosimilar approvals. What biosimilars are available? What trends are you seeing?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Nerandomilast for Idiopathic Pulmonary Fibrosis
2
Pulling Back Funding for Research Could Leave HIV Treatment in Worse State: Patrick Sullivan, DVM, PhD
3
FDA Approves Cemiplimab as First, Only Adjuvant Immunotherapy for High-Risk CSCC
4
Value-Based Care Interventions and Management of CKD Progression
5